An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Stopped The study stopped early, before enrolling its first participant.

Conditions

• Primary Biliary Cirrhosis

Interventions

• DRUG: LUM001

Sponsor

Mirum Pharmaceuticals, Inc.